We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Second wind

19 August 2015 By Robyn Mak

U.S.-listed WuXi PharmaTech has finalised a $3.5 bln takeover. Given China’s slumping stock market and slowing economy, persuading investors to put up $2 bln in fresh equity is impressive. There’s still hope for some of the two dozen other Chinese companies seeking to delist.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)